{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T19:25:12Z","timestamp":1795116312197,"version":"4.10.3"},"reference-count":90,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.antiviral.2009.09.001","type":"journal-article","created":{"date-parts":[[2009,9,9]],"date-time":"2009-09-09T12:36:33Z","timestamp":1252499793000},"page":"190-200","source":"Crossref","is-referenced-by-count":80,"title":["Pharmacogenetics of antiretrovirals"],"prefix":"10.1016","volume":"85","author":[{"given":"Valerio","family":"Tozzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2009.09.001_bib1","first-page":"341","article-title":"The Efavirenz induced increase in HDL-cholesterol is influenced by the multidrug resistance gene 1 C3435T polymorphism","volume":"19","author":"Alonso-Villaverde","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.09.001_bib2","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1086\/381678","article-title":"The cellular pharmacology of nucleoside and nucleotide-analogue reverse transcriptase inhibitors and its relationship to clinical toxicities","volume":"38","author":"Anderson","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.09.001_bib3","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/01.qai.0000225013.53568.69","article-title":"Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study","volume":"42","author":"Anderson","year":"2006","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2009.09.001_bib4","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/FPC.0b013e32814db8b7","article-title":"Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy","volume":"17","author":"Arnedo","year":"2007","journal-title":"Pharmacogenet. Genom."},{"key":"10.1016\/j.antiviral.2009.09.001_bib5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/GIM.0b013e3181632713","article-title":"IL-1beta (+3954C\/T) polymorphism could protect human immunodeficiency virus (HIV)-infected patients on highly active antiretroviral treatment (HAART) against lipodystrophic syndrome","volume":"10","author":"Asensi","year":"2008","journal-title":"Genet. Med."},{"key":"10.1016\/j.antiviral.2009.09.001_bib6","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/00126334-200404150-00014","article-title":"Hepatotoxicity associated with nevirapine use","volume":"35","author":"Baylor","year":"2004","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2009.09.001_bib7","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1592\/phco.24.17.1732.52347","article-title":"Atazanavir for the treatment of human immunodeficiency virus infection","volume":"24","author":"Busti","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.antiviral.2009.09.001_bib8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/sj.tpj.6500470","article-title":"The mitochondrial pharmacogenomics of haplogroup T: MTND2*LHON4917G and antiretroviral therapy-associated peripheral neuropathy","volume":"8","author":"Canter","year":"2008","journal-title":"Pharmacogenom. J."},{"key":"10.1016\/j.antiviral.2009.09.001_bib9","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(98)08468-2","article-title":"Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study","volume":"353","author":"Carr","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2009.09.001_bib10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/ACI.0b013e3282370c5f","article-title":"Human leukocyte antigens and drug hypersensitivity","volume":"7","author":"Chung","year":"2007","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"10.1016\/j.antiviral.2009.09.001_bib11","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0149-2918(02)80057-1","article-title":"The abacavir hypersensitivity reaction: a review","volume":"24","author":"Clay","year":"2002","journal-title":"Clin. Ther."},{"key":"10.1016\/j.antiviral.2009.09.001_bib12","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/QAI.0b013e3180ed44d9","article-title":"No evidence of relation between peripheral neuropathy and presence of hemochromatosis gene mutations in HIV-1-positive patients","volume":"46","author":"Costarelli","year":"2007","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2009.09.001_bib13","unstructured":"Department of Health and Human Services (DHHS), 2008. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. November 3, 2008. Available at: http:\/\/www.hivatis.org, accessed: May 16th, 2009."},{"key":"10.1016\/j.antiviral.2009.09.001_bib14","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1086\/381450","article-title":"Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors","volume":"38","author":"Dieterich","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.09.001_bib15","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00002030-199703110-00007","article-title":"Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals","volume":"11","author":"Eugen-Olsen","year":"1997","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.09.001_bib16","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1097\/00002030-200112070-00007","article-title":"An interaction between apoC-III variants and protease inhibitors contributes to high triglyceride\/low HDL levels in treated HIV patients","volume":"15","author":"Fauvel","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.09.001_bib17","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0140-6736(02)07276-8","article-title":"Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study","volume":"359","author":"Fellay","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2009.09.001_bib18","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1097\/01.aids.0000131356.52457.7a","article-title":"The role of CFTR and SPINK-1 mutations in pancreatic disorders in HIV-positive patients: a case\u2013control study","volume":"18","author":"Felley","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.09.001_bib19","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1371\/journal.pmed.0030052","article-title":"Association among race\/ethnicity, APOC-III genotypes, and lipids in HIV-1-infected individuals on antiretrovirals therapy","volume":"3","author":"Foulkes","year":"2006","journal-title":"PLos Med."},{"key":"10.1016\/j.antiviral.2009.09.001_bib20","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1086\/522175","article-title":"Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26","volume":"45","author":"Gatanaga","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.09.001_bib21","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/QAD.0b013e32801199d9","article-title":"HLA-Cw8 primarily associated with hypersensitivity to nevirapine","volume":"21","author":"Gatanaga","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.09.001_bib22","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1468-1293.2008.00636.x","article-title":"British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy","volume":"9","author":"Gazzard","year":"2008","journal-title":"HIV Med."},{"key":"10.1016\/j.antiviral.2009.09.001_bib23","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1373\/clinchem.2006.069583","article-title":"Protease inhibitor-associated dyslipidemia in HIV-infected patients is strongly influenced by the APOA5-1131T\u2192C gene variation","volume":"52","author":"Guardiola","year":"2006","journal-title":"Clin. Chem."},{"key":"10.1016\/j.antiviral.2009.09.001_bib24","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1086\/507097","article-title":"Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration","volume":"43","author":"Haas","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.09.001_bib25","first-page":"2391","article-title":"Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study","volume":"18","author":"Haas","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.09.001_bib26","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1086\/497610","article-title":"Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and\/or Nelfinavir: an Adult AIDS Clinical Trials Group Study","volume":"192","author":"Haas","year":"2005","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.09.001_bib27","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0198-8859(01)00322-6","article-title":"Influence of TNF-alpha gene polymorphisms on TNF-alpha production and disease","volume":"62","author":"Hajeer","year":"2001","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.antiviral.2009.09.001_bib28","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jama.300.5.555","article-title":"Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA Panel","volume":"300","author":"Hammer","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.antiviral.2009.09.001_bib29","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0140-6736(02)08158-8","article-title":"Genetic variations in HLA-B region and hypersensitivity reactions to abacavir","volume":"359","author":"Hetherington","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2009.09.001_bib30","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0149-2918(01)80132-6","article-title":"Hypersensitivity reactions during therapy with the nucleoside reverse trancriptase inhibitor abacavir","volume":"23","author":"Hetherington","year":"2001","journal-title":"Clin. Ther."},{"key":"10.1016\/j.antiviral.2009.09.001_bib31","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2174\/1389201033377300","article-title":"Human inter-individual DNA sequence variation in candidate genes, drug targets, the importance of haplotypes and pharmacogenomics","volume":"4","author":"Hoehe","year":"2003","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.antiviral.2009.09.001_bib32","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1517\/phgs.5.2.203.27481","article-title":"Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations","volume":"5","author":"Hughes","year":"2004","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.antiviral.2009.09.001_bib33","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/00008571-200406000-00002","article-title":"Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity","volume":"14","author":"Hughes","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.antiviral.2009.09.001_bib34","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1097\/01.aids.0000180786.02930.a1","article-title":"Mitochondrial haplogroups and peripheral neuropathy during antiretrovirals therapy: an adult AIDS clinical trials group study","volume":"19","author":"Hulgan","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.09.001_bib35","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1124\/mol.106.028233","article-title":"Functional involvement of multidrug resistance-associated protein 4 (MRP4\/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir","volume":"71","author":"Imaoka","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.antiviral.2009.09.001_bib36","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/508546","article-title":"Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy","volume":"194","author":"Izzedine","year":"2006","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.09.001_bib37","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1097\/01.aids.0000237366.56864.3c","article-title":"Hemocromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy","volume":"20","author":"Kallianpur","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.09.001_bib38","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1097\/00002030-200211080-00002","article-title":"HIV-associated sensory neuropathies","volume":"16","author":"Keswani","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.09.001_bib39","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00126334-200301010-00007","article-title":"Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients","volume":"32","author":"Lichtenstein","year":"2003","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2009.09.001_bib40","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1097\/01.aids.0000238408.82947.09","article-title":"HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients","volume":"20","author":"Littera","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.09.001_bib41","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0092-8674(00)80110-5","article-title":"Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection","volume":"86","author":"Liu","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2009.09.001_bib42","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.biopha.2007.04.008","article-title":"Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project","volume":"62","author":"Madeddu","year":"2008","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.antiviral.2009.09.001_bib43","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1097\/00002030-200210180-00005","article-title":"TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy","volume":"16","author":"Maher","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.09.001_bib44","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","article-title":"Association between presence of HLA-B*5701, HLA-DR7 and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir","volume":"359","author":"Mallal","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2009.09.001_bib45","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B*5701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2009.09.001_bib46","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1073\/pnas.0307067101","article-title":"Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant","volume":"101","author":"Martin","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2009.09.001_bib47","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00002030-200501030-00014","article-title":"Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts","volume":"19","author":"Martin","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.09.001_bib48","first-page":"1192","article-title":"Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients","volume":"15","author":"Marzolini","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.09.001_bib49","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clpt.2003.09.012","article-title":"Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance","volume":"75","author":"Marzolini","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2009.09.001_bib50","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0140-6736(96)91273-8","article-title":"Genetic variation in bilirubin UPD-glucuronofyltransferase gene promoter and Gilbert's syndrome","volume":"347","author":"Monaghan","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2009.09.001_bib51","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/01.fpc.0000230413.97596.fa","article-title":"Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study","volume":"16","author":"Motsinger","year":"2006","journal-title":"Pharmacogenet. Genom."},{"key":"10.1016\/j.antiviral.2009.09.001_bib52","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1586\/14787210.4.4.523","article-title":"Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone","volume":"4","author":"Mu\u00f1oz de Benito","year":"2006","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.antiviral.2009.09.001_bib53","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00002030-200301030-00017","article-title":"Tumor necrosis factor-alpha gene \u2212238G\/A promoter polymorphism associated with a more rapid onset of lipodystrophy","volume":"17","author":"Nolan","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.09.001_bib54","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1345\/aph.1A022","article-title":"Hypersensitivity related to abacavir in two members of a family","volume":"35","author":"Peyrie\u00e8re","year":"2001","journal-title":"Ann. Parmacother."},{"key":"10.1016\/j.antiviral.2009.09.001_bib55","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1086\/504874","article-title":"Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study","volume":"43","author":"Rauch","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.09.001_bib56","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1086\/499364","article-title":"Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study","volume":"42","author":"Ribaudo","year":"2006","journal-title":"Clin. Inf. Dis."},{"key":"10.1016\/j.antiviral.2009.09.001_bib57","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1086\/507101","article-title":"Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse transcriptase inhibitor hepatotoxicity","volume":"43","author":"Ritchie","year":"2006","journal-title":"Clin. Inf. Dis."},{"key":"10.1016\/j.antiviral.2009.09.001_bib58","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1128\/AAC.42.3.612","article-title":"Anti-human immunedeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis(isopropyloxymethylcarbonyl)PMPA","volume":"42","author":"Robbins","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2009.09.001_bib59","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/499056","article-title":"Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C\/T polymorphism at the multidrug resistance gene 1","volume":"42","author":"Rodriguez-Novoa","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.09.001_bib60","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/QAD.0b013e328011d7c1","article-title":"Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia","volume":"21","author":"Rodriguez-Novoa","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.09.001_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01213011-200501000-00001","article-title":"Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients","volume":"15","author":"Rotger","year":"2005","journal-title":"Pharmacogenet. Genom."},{"key":"10.1016\/j.antiviral.2009.09.001_bib62","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1086\/466531","article-title":"Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia","volume":"192","author":"Rotger","year":"2005","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.09.001_bib63","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/sj.clpt.6100072","article-title":"Predictive value of know and novel alleles of CYP2B6 for Efavirenz plasma concentrations in HIV-infected individuals","volume":"81","author":"Rotger","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2009.09.001_bib64","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1097\/00002030-199912240-00002","article-title":"Fat distribution and metabolic changes in patients with HIV infection","volume":"13","author":"Safrin","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.09.001_bib65","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/QAI.0b013e318040b29e","article-title":"Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516-T polymorphism","volume":"45","author":"Saitoh","year":"2007","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2009.09.001_bib66","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/382722a0","article-title":"Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene","volume":"382","author":"Samson","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2009.09.001_bib67","series-title":"11th European AIDS Conference","article-title":"Effect of CCR5 locus polymorphisms on virological response to maraviroc in antiretroviral-experienced individuals with CCR5-tropic HIV-1 in MOTIVATE 1 and 2","author":"Sanders","year":"2007"},{"key":"10.1016\/j.antiviral.2009.09.001_bib68","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1097\/01.aids.0000191485.92285.c7","article-title":"Self-perception of body changes in persons living with HIV\/AIDS: prevalence and associated factors","volume":"19","author":"Santos","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.09.001_bib69","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/12487","article-title":"MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs","volume":"5","author":"Schuetz","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2009.09.001_bib70","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1038\/ng1558","article-title":"Toward genome-wide SNP genotyping","volume":"37","author":"Syvanen","year":"2005","journal-title":"Nat. Genet."},{"key":"10.1016\/j.antiviral.2009.09.001_bib71","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1258\/095646206777323346","article-title":"Nevirapine toxicity","volume":"17","author":"Taiwo","year":"2006","journal-title":"Int. J. STD AIDS"},{"key":"10.1016\/j.antiviral.2009.09.001_bib72","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1086\/429295","article-title":"Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders","volume":"191","author":"Tarr","year":"2005","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.09.001_bib73","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1592\/phco.28.6.782","article-title":"Successful use of reduced-dose efavirenz in a patient with human immunodeficiency virus infection: case report and review of the literature","volume":"28","author":"Torno","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.antiviral.2009.09.001_bib74","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.bbrc.2004.05.116","article-title":"Homozygous CYP2B6*6 (Q172h and K262R) correlates with high plasma efavirenz concentration in HIV-1 patients treated with standard efavirenz-containing regimens","volume":"319","author":"Tsuchiya","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.antiviral.2009.09.001_bib75","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1086\/373937","article-title":"Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease","volume":"72","author":"van der Walt","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.antiviral.2009.09.001_bib76","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1097\/00002030-199212000-00008","article-title":"The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study","volume":"6","author":"van Leeuwen","year":"1992","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.09.001_bib77","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/QAD.0b013e3282f37812","article-title":"HLA-DRB1*0101 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz","volume":"22","author":"Vitezica","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.09.001_bib78","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0378-1119(99)00295-4","article-title":"Mitochondrial DNA variation in human evolution and disease","volume":"238","author":"Wallace","year":"1999","journal-title":"Gene"},{"key":"10.1016\/j.antiviral.2009.09.001_bib79","first-page":"171","article-title":"Mitochondrial DNA sequence variation in human evolution and disease","volume":"100","author":"Wallace","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2009.09.001_bib80","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1097\/QAD.0b013e3282efad32","article-title":"Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection","volume":"21","author":"Wand","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.09.001_bib81","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/01.fpc.0000178311.02878.83","article-title":"Multidrug resistance polypeptide 1 (MDR1, ABCB1) variants 3455C>T affects mRNA stability","volume":"15","author":"Wang","year":"2005","journal-title":"Pharmacogenet. Genom."},{"key":"10.1016\/j.antiviral.2009.09.001_bib82","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/01.fpc.0000189797.03845.90","article-title":"Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz","volume":"16","author":"Wang","year":"2006","journal-title":"Pharmacogenet. Genom."},{"key":"10.1016\/j.antiviral.2009.09.001_bib83","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/clpt.2009.12","article-title":"Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms","volume":"85","author":"Wenning","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2009.09.001_bib84","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/095632020501600601","article-title":"CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection","volume":"16","author":"Westby","year":"2005","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2009.09.001_bib85","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1476-0711-4-3","article-title":"No influence of the P-glycoprotein polymorphisms MDR1 G2677T\/A and C3435T on the virological and immunological response in treatment of naive HIV-positive patients","volume":"4","author":"Winzer","year":"2005","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"10.1016\/j.antiviral.2009.09.001_bib86","first-page":"531","article-title":"No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment","volume":"8","author":"Winzer","year":"2003","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.antiviral.2009.09.001_bib87","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1086\/507333","article-title":"Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy","volume":"43","author":"Wohl","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.09.001_bib88","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/jac\/dkn029","article-title":"Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentration in HIV infected patients","volume":"61","author":"Wyen","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2009.09.001_bib89","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.tem.2006.07.001","article-title":"Adrenergic receptor polymorphism and autonomic nervous system function in human obesity","volume":"17","author":"Yasuda","year":"2006","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.antiviral.2009.09.001_bib90","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1097\/QAD.0b013e32830b3a96","article-title":"Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy","volume":"22","author":"Zanone Poma","year":"2008","journal-title":"AIDS"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354209004537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354209004537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T13:01:00Z","timestamp":1633870860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354209004537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0166354209004537"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2009.09.001","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}